Home › Knee Osteoarthritis › NCT05985785

Bone Marrow Aspirate Concentrate (BMAC) vs Corticosteroid Injection

Bone Marrow Aspirate Concentrate vs Corticosteroid Injection for Symptomatic Osteoarthritis (OA) of the Knee: A Randomized Controlled Trial

Who can join

Ages 18 to 70 · All sexes

Inclusion Criteria:

* Patients between the ages of 18-70
* Long standing knee pain from osteoarthritis (KL grade 2-3) despite conventional treatments such as activity modification, weight loss, physical therapy, analgesics, nonsteroidal anti-inflammatory drugs, or injection therapy for at least 6 weeks
* 7-day average pain score of at least 4 on VAS scale

Exclusion Criteria:

* Systemic diseases (Diabetes, malignancies, infections, etc.)
* Post-traumatic arthritis
* Patient had intra-articular injection on affected knee in last three months

About the study

Prospective single-masked (study participant will be masked), randomized controlled trial to examine the influence of BMAC on patient-reported outcomes (PROs) in patients with primary knee osteoarthritis.

What is being tested

• Autologous bone marrow aspirate concentrate (BMAC) (other)
• Corticosteroid injections (drug)
• Crossover Autologous bone marrow aspirate concentrate (BMAC) (other)

Sponsor: Rush University Medical Center · Participants: 100 · Started: Jul 19, 2022

Contact the study team

• Carla M. Edwards, PhD · Phone: 312-563-5735
• Jorge Chahla, MD · Phone: (312) 432-2818

Official record on ClinicalTrials.gov — NCT05985785

Locations in the U.S.

Conditions

• Knee Osteoarthritis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.